Siena Restaurant

Siena Biotech was an Italian drug discovery company focused on developing novel therapies for neurodegenerative diseases and oncology. The company's primary research efforts targeted conditions with high unmet medical needs, such as Huntington's disease and Alzheimer's disease, utilizing a small molecule approach. Its lead candidate, selisistat (SEN0014196), was a first-in-class sirtuin 1 inhibitor that reached Phase 2 clinical trials for Huntington's disease. Despite establishing significant partnerships with major pharmaceutical firms like Wyeth and Roche, the company faced financial difficulties and entered liquidation in 2015. Siena Biotech was a key player in the European biotechnology ecosystem, particularly within the Tuscany Life Sciences cluster.